Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack U Flanagan

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Journal of Medicinal Chemistry|December 10, 2009
4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell deathMichael P Hay, Sandra Turcotte, Jack U Flanagan, et al.
Acta Pharmaceutica Sinica. B|October 26, 2019
Orthogonal assays for the identification of inhibitors of the single-stranded nucleic acid binding protein YB-1AlexanderJ Trevarton, Yan Zhou, Dehua Yang, et al.
The Biochemical Journal|May 21, 2017
Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivityGrace Q Gong, Jackie D Kendall, James M J Dickson, et al.
BMC Cancer|February 7, 2021
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEKKhanh B Tran, Sharada Kolekar, Anower Jabed, et al.
European Journal of Medicinal Chemistry|March 5, 2013
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3Daniel M Heinrich, Jack U Flanagan, Stephen M F Jamieson, et al.
Structure (London, England : 1993)|February 9, 2005
An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1Anna Aagaard, Pawel Listwan, Nathan Cowieson, et al.
Journal of Medicinal Chemistry|October 16, 2004
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibitionCarol A Kemp, Jack U Flanagan, Annamaria J van Eldik, et al.
Protein Engineering, Design & Selection : PEDS|October 27, 2005
Modelling the structure of latexin-carboxypeptidase A complex based on chemical cross-linking and molecular dockingDmitri Mouradov, Ari Craven, Jade K Forwood, et al.
BMC Research Notes|September 6, 2008
Identification of a non-purple tartrate-resistant acid phosphatase: an evolutionary link to Ser/Thr protein phosphatases?Kieran S Hadler, Thomas Huber, A Ian Cassady, et al.
The Biochemical Journal|March 3, 2004
Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metaboliteJack U Flanagan, Jean-Didier Maréchal, Richard Ward, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|December 10, 2009
4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell deathMichael P Hay, Sandra Turcotte, Jack U Flanagan, et al.
Acta Pharmaceutica Sinica. B|October 26, 2019
Orthogonal assays for the identification of inhibitors of the single-stranded nucleic acid binding protein YB-1AlexanderJ Trevarton, Yan Zhou, Dehua Yang, et al.
The Biochemical Journal|May 21, 2017
Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivityGrace Q Gong, Jackie D Kendall, James M J Dickson, et al.
BMC Cancer|February 7, 2021
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEKKhanh B Tran, Sharada Kolekar, Anower Jabed, et al.
European Journal of Medicinal Chemistry|March 5, 2013
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3Daniel M Heinrich, Jack U Flanagan, Stephen M F Jamieson, et al.
Structure (London, England : 1993)|February 9, 2005
An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1Anna Aagaard, Pawel Listwan, Nathan Cowieson, et al.
Journal of Medicinal Chemistry|October 16, 2004
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibitionCarol A Kemp, Jack U Flanagan, Annamaria J van Eldik, et al.
Protein Engineering, Design & Selection : PEDS|October 27, 2005
Modelling the structure of latexin-carboxypeptidase A complex based on chemical cross-linking and molecular dockingDmitri Mouradov, Ari Craven, Jade K Forwood, et al.
BMC Research Notes|September 6, 2008
Identification of a non-purple tartrate-resistant acid phosphatase: an evolutionary link to Ser/Thr protein phosphatases?Kieran S Hadler, Thomas Huber, A Ian Cassady, et al.
The Biochemical Journal|March 3, 2004
Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metaboliteJack U Flanagan, Jean-Didier Maréchal, Richard Ward, et al.
Pageof 7